Taipei, Taiwan

Min-Yu Tsai

This inventor holds 1 USPTO granted patent. Top assignee: International Business Machines Corporation. Active years: 2018.


% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2018

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Min-Yu Tsai: Innovator in Proton Therapy Dose Calculations

Introduction

Min-Yu Tsai is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of medical physics, particularly in the area of proton therapy. His innovative work focuses on enhancing the accuracy and efficiency of dose calculations in proton therapy treatments.

Latest Patents

Min-Yu Tsai holds a patent for "Fast and accurate proton therapy dose calculations." This invention involves simulating particle beam interactions by identifying a set of functions corresponding to various physical aspects of a particle beam. The process includes performing simulations using a full physics model, selecting distribution functions that model relevant behavior, and reducing computation time by replacing complex functions with simpler distribution functions. This method allows for accurate modeling of relevant behaviors while optimizing runtime and accuracy criteria in Monte Carlo simulations. He has 1 patent to his name.

Career Highlights

Min-Yu Tsai is associated with International Business Machines Corporation, commonly known as IBM. His work at IBM has allowed him to collaborate with leading experts in the field and contribute to groundbreaking advancements in medical technology.

Collaborations

Some of his notable coworkers include Anne Elizabeth Gattiker and Damir Anthony Jamsek. Their collaborative efforts have further enhanced the research and development of innovative solutions in proton therapy.

Conclusion

Min-Yu Tsai's contributions to proton therapy dose calculations exemplify the impact of innovation in medical physics. His work not only advances treatment methodologies but also improves patient outcomes in cancer therapy.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…